• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硅胶干凝胶作为用于药物控释的可植入载体——植入后药物分布及组织效应评估

Silica xerogel as an implantable carrier for controlled drug delivery--evaluation of drug distribution and tissue effects after implantation.

作者信息

Kortesuo P, Ahola M, Karlsson S, Kangasniemi I, Yli-Urpo A, Kiesvaara J

机构信息

Orion Corporation, Orion Pharma, Pharmaceutical Development Department, Turku, Finland.

出版信息

Biomaterials. 2000 Jan;21(2):193-8. doi: 10.1016/s0142-9612(99)00148-9.

DOI:10.1016/s0142-9612(99)00148-9
PMID:10632401
Abstract

The purpose of the present study was to examine controlled delivery of toremifene citrate from subcutaneously implanted silica xerogel carrier and to evaluate silica xerogel related tissue effects after implantation. Toremifene citrate was incorporated into hydrolyzed silica sol in a room temperature process. Toremifene citrate treated silica xerogel implants were tested both in vitro and in vivo using healthy mice. Silica xerogel with tritium-labelled toremifene was implanted subcutaneously in mice for 42 d. To determine the amount of tritiated toremifene remaining in the silica discs at the implantation site, the discs were excised periodically and radioactivity measured. The amount of tritiated toremifene in the implant after 42 d was still about 16% and the amount of silica xerogel about 25%. In a histopathological study silica xerogel did not show any tissue irritation at the site of the implantation. A fibrotic capsule was formed around the implant. No silica xerogel related histological changes in liver, kidney, lymph nodes and uterus were observed during the implantation period. The silica xerogel discs showed a sustained release of toremifene citrate over 42 d. Histologically, toremifene-related changes in the uterus were also detectable at all studied time points. These findings suggest that silica xerogel is a promising carrier material for implantable controlled drug delivery system.

摘要

本研究的目的是检测皮下植入的硅胶干凝胶载体对枸橼酸托瑞米芬的控释效果,并评估植入后硅胶干凝胶对组织的影响。在室温条件下,将枸橼酸托瑞米芬加入水解硅溶胶中。使用健康小鼠对经枸橼酸托瑞米芬处理的硅胶干凝胶植入物进行体外和体内测试。将含有氚标记枸橼酸托瑞米芬的硅胶干凝胶皮下植入小鼠体内42天。为了确定植入部位硅胶圆片中剩余的氚标记枸橼酸托瑞米芬的量,定期切除圆片并测量放射性。42天后,植入物中氚标记枸橼酸托瑞米芬的量仍约为16%,硅胶干凝胶的量约为25%。在组织病理学研究中,硅胶干凝胶在植入部位未显示任何组织刺激。植入物周围形成了一层纤维囊。在植入期间,未观察到硅胶干凝胶对肝脏、肾脏、淋巴结和子宫的组织学变化。硅胶干凝胶圆片在42天内显示出枸橼酸托瑞米芬的持续释放。在组织学上,在所有研究时间点均能检测到子宫中与托瑞米芬相关的变化。这些发现表明,硅胶干凝胶是一种有前景的可植入控释药物递送系统的载体材料。

相似文献

1
Silica xerogel as an implantable carrier for controlled drug delivery--evaluation of drug distribution and tissue effects after implantation.硅胶干凝胶作为用于药物控释的可植入载体——植入后药物分布及组织效应评估
Biomaterials. 2000 Jan;21(2):193-8. doi: 10.1016/s0142-9612(99)00148-9.
2
Sol-gel-processed sintered silica xerogel as a carrier in controlled drug delivery.
J Biomed Mater Res. 1999 Feb;44(2):162-7. doi: 10.1002/(sici)1097-4636(199902)44:2<162::aid-jbm6>3.0.co;2-p.
3
Silica xerogel carrier material for controlled release of toremifene citrate.用于柠檬酸托瑞米芬控释的二氧化硅干凝胶载体材料。
Int J Pharm. 2000 Feb 15;195(1-2):219-27. doi: 10.1016/s0378-5173(99)00403-2.
4
In vitro evaluation of biodegradable epsilon-caprolactone-co-D, L-lactide/silica xerogel composites containing toremifene citrate.
Int J Pharm. 1999 Apr 30;181(2):181-91. doi: 10.1016/s0378-5173(99)00022-8.
5
Effect of the molecular weight of poly(epsilon-caprolactone-co-DL-lactide) on toremifene citrate release from copolymer/silica xerogel composites.
Int J Pharm. 2001 Jan 5;212(1):121-30. doi: 10.1016/s0378-5173(00)00601-3.
6
In vitro evaluation of sol-gel processed spray dried silica gel microspheres as carrier in controlled drug delivery.
Int J Pharm. 2000 May 10;200(2):223-9. doi: 10.1016/s0378-5173(00)00393-8.
7
In vitro release behavior of toremifene citrate from sol-gel processed sintered silica xerogels.
Drug Dev Ind Pharm. 1999 Aug;25(8):955-9. doi: 10.1081/ddc-100102257.
8
[Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].[托瑞米芬和他莫昔芬给药后体内分布及其给药方案的评估]
Gan To Kagaku Ryoho. 2002 Jun;29(6):881-7.
9
[Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
Gan To Kagaku Ryoho. 2000 Feb;27(2):245-9.
10
Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release.用于抗生素控释的二氧化硅溶胶-凝胶。I. 合成、表征及体外释放
J Biomed Mater Res. 2001 Nov;57(2):313-20. doi: 10.1002/1097-4636(200111)57:2<313::aid-jbm1173>3.0.co;2-e.

引用本文的文献

1
Mesoporous biophotonic carbon spheres with tunable curvature for intelligent drug delivery.具有可调曲率的介孔生物光子碳球用于智能药物递送。
Nanophotonics. 2022 Oct 4;11(22):5165-5175. doi: 10.1515/nanoph-2022-0523. eCollection 2022 Dec.
2
Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy.棒状介孔硅纳米颗粒通过阻断脂噬减少蟾毒灵的心脏毒性并抑制结肠癌。
Lipids Health Dis. 2024 Sep 27;23(1):318. doi: 10.1186/s12944-024-02301-y.
3
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.
可注射生物可降解二氧化硅贮库:降血糖肽普兰林肽两个月的持续释放
Pharmaceutics. 2022 Mar 2;14(3):553. doi: 10.3390/pharmaceutics14030553.
4
Synthesis of water-degradable silica nanoparticles from carbamate-containing bridged silsesquioxane precursor.由含氨基甲酸酯的桥连倍半硅氧烷前体合成可水解的二氧化硅纳米颗粒。
RSC Adv. 2018;8(9):4914-4920. doi: 10.1039/C7RA12377A. Epub 2018 Jan 29.
5
Glutathione-sensitive hollow mesoporous silica nanoparticles for controlled drug delivery.谷胱甘肽敏感的中空介孔硅纳米颗粒用于控制药物递送。
J Control Release. 2018 Jul 28;282:62-75. doi: 10.1016/j.jconrel.2018.04.032. Epub 2018 Apr 19.
6
Electrospun Polyhydroxybutyrate/Poly(ε-caprolactone)/Sol-Gel-Derived Silica Hybrid Scaffolds with Drug Releasing Function for Bone Tissue Engineering Applications.用于骨组织工程应用的具有药物释放功能的静电纺丝聚羟基丁酸酯/聚(ε-己内酯)/溶胶-凝胶衍生硅 hybridscaffolds。
ACS Appl Mater Interfaces. 2018 May 2;10(17):14540-14548. doi: 10.1021/acsami.8b02656. Epub 2018 Apr 17.
7
Graphene based scaffolds on bone tissue engineering.基于石墨烯的骨组织工程支架。
Bioengineered. 2018 Jan 1;9(1):38-47. doi: 10.1080/21655979.2017.1373539. Epub 2017 Nov 30.
8
Preparation and Characterization of Double Shell FeO Cluster@Nonporous SiO@Mesoporous SiO Nanocomposite Spheres and Investigation of their Biocompatibility.双壳层FeO团簇@无孔SiO@介孔SiO纳米复合球体的制备、表征及其生物相容性研究
Iran J Biotechnol. 2015 Mar;13(1):1-10. doi: 10.15171/ijb.1068.
9
Silica microparticles for sustained zero-order release of an anti-CD40L antibody.载有抗 CD40L 抗体的二氧化硅微球用于持续零级释放。
Drug Deliv Transl Res. 2018 Apr;8(2):368-374. doi: 10.1007/s13346-017-0408-1.
10
Cytokine induction of sol-gel-derived TiO and SiO coatings on metallic substrates after implantation to rat femur.植入大鼠股骨后,金属基底上溶胶-凝胶衍生的TiO和SiO涂层的细胞因子诱导作用。
Int J Nanomedicine. 2017 Feb 28;12:1639-1645. doi: 10.2147/IJN.S114885. eCollection 2017.